146 related articles for article (PubMed ID: 28476823)
41. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
Gallos ID; Shehmar M; Thangaratinam S; Papapostolou TK; Coomarasamy A; Gupta JK
Am J Obstet Gynecol; 2010 Dec; 203(6):547.e1-10. PubMed ID: 20934679
[TBL] [Abstract][Full Text] [Related]
42. Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy.
Sletten ET; Smaglyukova N; Ørbo A; Sager G
J Steroid Biochem Mol Biol; 2020 Sep; 202():105701. PubMed ID: 32479983
[TBL] [Abstract][Full Text] [Related]
43. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study.
Scarselli G; Bargelli G; Taddei GL; Marchionni M; Peruzzi E; Pieralli A; Mattei A; Buccoliero AM; Fambrini M
Fertil Steril; 2011 Jan; 95(1):420-2. PubMed ID: 20723889
[TBL] [Abstract][Full Text] [Related]
44. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
van der Meer AC; Hanna LS
Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
[TBL] [Abstract][Full Text] [Related]
45. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
Weng M; Li L; Feng S; Xie M; Hong S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
[TBL] [Abstract][Full Text] [Related]
46. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
47. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
[TBL] [Abstract][Full Text] [Related]
49. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
[TBL] [Abstract][Full Text] [Related]
50. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
51. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
[TBL] [Abstract][Full Text] [Related]
52. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
53. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
55. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
Depypere H; Inki P
Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
[TBL] [Abstract][Full Text] [Related]
56. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
Qi X; Zhao W; Duan Y; Li Y
Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
[TBL] [Abstract][Full Text] [Related]
57. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
[TBL] [Abstract][Full Text] [Related]
58. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
59. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients.
Morelli M; Sacchinelli A; Venturella R; Mocciaro R; Zullo F
J Obstet Gynaecol Res; 2013 May; 39(5):985-90. PubMed ID: 23551827
[TBL] [Abstract][Full Text] [Related]
60. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
